Clinical Trial Update: CR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral Function [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 clinical trial evaluating AT1 receptor blockade and ACE inhibition on humoral function in cardiorenal syndrome; status completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiorenal Syndrome

Snippet

Sponsor: Mayo Clinic | Conditions: Cardiorenal Syndrome (CRS) | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-11-18